Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Total Current Liabilities (2016 - 2025)

Aptevo Therapeutics' Total Current Liabilities history spans 11 years, with the latest figure at $5.6 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 4.56% year-over-year to $5.6 million; the TTM value through Sep 2025 reached $5.6 million, down 4.56%, while the annual FY2024 figure was $6.2 million, 14.08% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $5.6 million at Aptevo Therapeutics, up from $4.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $34.8 million in Q4 2021 and bottomed at $4.9 million in Q2 2025.
  • The 5-year median for Total Current Liabilities is $6.9 million (2023), against an average of $12.7 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 340.79% in 2021 before it plummeted 77.31% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $34.8 million in 2021, then plummeted by 74.95% to $8.7 million in 2022, then fell by 17.02% to $7.2 million in 2023, then decreased by 14.08% to $6.2 million in 2024, then dropped by 9.55% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Total Current Liabilities are $5.6 million (Q3 2025), $4.9 million (Q2 2025), and $5.4 million (Q1 2025).